SEC Tracker
Get the app

Odyssey Health ODYY

Odyssey Health Q2 FY25: net loss $220K; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Odyssey Health reported for Q2 FY25, the quarter ended Jan 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$220K−102% from $13.3M in Q2 FY2410-Q income statement, on EDGAR
  2. Diluted EPS$0.00−100% from $0.12 in Q2 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$7K−96% from $166K in Q2 FY2410-Q balance sheet, on EDGAR
  4. Cash from operations−$47KAgainst −$908K in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Odyssey Health files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Autonomix Medical AMIX public float $6M, Sep 30, 2025
  2. Sonoma Pharmaceuticals SNOA public float $6M, Sep 30, 2025
  3. Family Office of America FOFA public float $6M, Jun 30, 2025
  4. Adm Tronics Unlimited ADMT public float $7M, Sep 30, 2025
  5. Aethlon Medical AEMD public float $6M, Sep 30, 2025